Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific is viewed positively because it has reduced reliance on commoditized cardiac rhythm management and drug-eluting stents by building a more diversified, higher-growth portfolio through product innovation and M&A, supported by a healthy balance sheet, investment-grade credit, and more than 40 deals over the past ten years. Its growth outlook is anchored by multiple “shots on goal,” including Watchman, Farapulse, renal denervation, and planned launches that should expand the PFA and LAAC platforms, while management expects about $500 million in restructuring savings within the next three years and has already stated that growth should improve meaningfully in 2028. Even with near-term pressure from Watchman and EP, the company’s above-7% weighted-average market growth rate, global reach with roughly 36% foreign sales, and the potential for share gains and operating leverage support a constructive long-term fundamental case.

Boston Scientific is facing a deteriorating fundamental setup as Q4 revenue is guided to decline 1%-3%, below Street expectations, while 2026 organic growth was cut to 3.75% from 5%-6% and EPS guidance was reduced to $3.16-$3.18. Management’s warning that 2027 will be “challenged” for both sales and EPS, combined with delays to FarawaveUltra, Faraflex, and other pipeline catalysts, suggests that key growth drivers in EP and Watchman are slipping just as competition, China pricing pressure, and cyberattack-related disruption intensify. Margin pressure from a weaker product mix, higher supply-chain and quality investments, and a tax rate of 12% further limits operating leverage, making the path to a durable recovery more uncertain.